Saratov JOURNAL of Medical and Scientific Research

Community-acquired pneumonia: biomarkers of inflammation and Omega-3 polyunsaturated fatty acids

Year: 2014, volume 10 Issue: №1 Pages: 173-178
Heading: Parmacology Article type: Review
Authors: Burbello A.T., Gaikovaya L.B., Pokladova M.V., Komok M.V., Kostyitsyna M.A.
Organization: North-West State Medical University n.a. I.I. Mechnikov, Department of Neuropathology Assistant Professor, Candidate of Medical Science

Based on the published data the role of inflammation in development of pneumonia has been discussed. The role of inflammatory mediators and laboratory markers for diagnostics of community acquired pneumonia is evaluated, as well as prognostic role of different biomarkers of inflammation, available for clinical laboratories, but not widely used in daily clinical practice. Influence of Omega-3 polyunsaturated fatty acids on inflammatory processes and possibilities to use them in the treatment of community acquired pneumonia is also discussed in the study.

1. Sinopalnikov Al, Kozlov RS. Community-acquired respiratory tract infections: guidelines for clinicians. SPb.: Premer MT, Nash Gorod, 2007; 352 p.; 2. Yakovlev SV. Community-acquired pneumonia in the elderly: particular etiology, clinical course and antibiotic therapy Russian Medical Journal 1999; 7 (16(98): 763-768; 3. Chuchalin AG, Sinopalnikov Al, Kozlov Rl, et al. Community-Acquired Pneumonia: Guidelines on diagnosis, Treatment and Prophylaxis. Guidelines for Clinicians (approved by the Ministry of Health of Russian Federation). Clinical Microbiology and Antimicrobial Chemotherapy 2010; 12(3): 186-224; 4. Novikov YK. Diagnosis and treatment of community-acquired pneumonia. Russian Medical Journal 2001; 3(1-2)6: 11-16; 5. Strachunskiy LS. Antibiotic therapy of community-acquired pneumonia in an outpatient setting. Consilium medicum 2002; 4(4): 180.; 6. Houck РМ, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-aquired pneumonia. Arch Intern Med 2004; 164(6): 637-44; 7. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275(2): 134-41; 8. Lim WS, van der Erden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58(5): 377-82; 9. Yandiola PP, CapelasteguiA, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135(6): 1572-9; 10. Dvoretskiy LI, Aleksandrova MA. Clinical guidelines for the diagnosis and treatment of community-acquired pneumonia. Russian Medical Journal 2010; 9: 522-529; 11. Torabinejad М, Cotti Е, Lessard G. Leukotrienes: their possible role in pulmal and periapical diseases. Endod dent Traumatol 1991;7:233-241; 12. Bisgard H, Pedersen M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 1987; 17(2): 95-103; 13. Karaulov AV, Silvestrov VP, et al. The role of eicosanoids: prostaglandins, prostacyclin, thromboxane and leukotrienes in the pathogenesis of asthma and other lung diseases. Therapeutic Archive 1986; 3: 123-130; 14. Masuev КА Eicosanoids and asthma. Pulmonology 1993; 1: 78-81; 15. Pasechnikov VD. Lipooxygenase synthesis of arachidonic acid metabolites and their role in the pathogenesis of inflammation of the gastric mucosa. Clinical Medicine 1991; 9: 69-72; 16. Kolosov VP, Kochegarova EYu, Naryshkina SV. Community-acquired pneumonia (clinical course, predicting outcomes). Blagoveshchensk, 2012; 124 p.; 17. Velkov VV Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 1. Clinical and laboratory consilium. Scientific-Practical Journal 2008; 6(25): 46-52; 18. Velkov VV. Procalcitonin and C-reactive protein in modern laboratory diagnostics. Part 2. Clinical and laboratory consilium. Scientific-Practical Journal 2009; 1 (26): 34-48; 19. Titov VN. C-reactive protein: physico-chemical properties, structure and specific properties. Clinical Laboratory Diagnostics 2004; 8: 3-10; 20. Geltser Bl, Kukol LV. Clinical estimation the effectiveness of prognostic scales in patients with community-acquired pneumonia. Clinical Medicine 2003; 11: 62-66; 21. Korppi М, Kroger L. C-reactive protein in viral and bacterial respiratory infection. Scand J Infect Dis 1993; 25 (2): 207-213; 22. Paltsev MA, Ivanov AA, Severin SV. Intercellular interactions. 2nd edition, revised and enlarged. Moscow: Meditsina, 2003; 288 p.; 23. Volozhin Al, Poryadkin GV, et al. Pathophysiology Moscow: Akademiya, 2006; 1: 272 p.; 24. Baymakanova GE, Zubairova PA, Avdeev SN, et al. Features of the clinical picture and community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Pulmonology 2009; 2: 33-41; 25. Shevchenko OP High-sensitivity analysis of C-reactive protein and its application in cardiology. Laboratory medicine 2003; 6: 35-41; 26. Meisner М., Tschaikowsky К., Palmaers Т., et al. Т. Comparison of procalcitonin(PCT) and C-reactive protein(CRP) plasma concentration at different SOFA scores during the course of sepsis and MDOS. Crit Care 1999; 3(1): 45-50; 27. Zubairova PA. Features of the clinical picture, prognosis and the role of biomarkers of inflammation in patients with pneumonia, chronic obstructive pulmonary disease: PhD abstract. Moscow, 2010; 114 p.; 28. Wicher J, Bienvenu J, Monneret G. Procalcitonin as an acture phase marker. Ann Clin Biochem 2001; 38(Pt5): 438-493; 29. Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000; 28 (9): 3171-6; 30. Christ-Crain M, Muller B. Procalcitoninum in bacterial infections: hype, hope, more or less? Swiss Med Wkly 2005; 135 (31-32): 451-460; 31. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in icritically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34(7): 1996-2003; 32. Joram N, Boscher C, Denizot S, et al. Umbilical cord blood procalcitonin C-reactive protein concentration as markers for early diagnosis of very early onset neonatal infection. Arch Dis Child Fetal Neonatal Ed 2006; 91(1): 65-66; 33. Chiesa C, Panero A, Rossi N. Reliability of procalcitonin concentration for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis1998; 26(3): 664-672; 34. Dandola P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab1994;79(6): 1605-8; 35. Simbirtsev AS. Cytokines: classification and biological functions. Cytokines and Inflammation 2004; 3(2): 16-21; 36. Brunkhorst FM, Wegscheider К, Forycky ZE, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26(2): 148-52; 37. Tarasova IV «Kapellmeister» intercellular interactions -cytokines. Allergology and immunology in pediatrics 2011; 1(24): 36-40; 38. Kostyushko AV, Markelova EV. Cytokine profile enterobacterial pneumonia in the experiment. Patologicheskaya fiziologiya i eksperimental'naya meditsina 2010; 4: 27-31; 39. Simbirtsev AS. Cytokines: classification and biological functions. Cytokines and Inflammation 2004; 3(2): 9-14; 40. RydkovskayaAV, Simbirtsev AS. Functional polymorphism of TNF-a and pathology. Cytokines and Inflammation 2007; 4(3): 4-10; 41. Harris МС, Costarino AT Jr, Sullivan JS, et al. Cytokine elevations in critically ill infants with sepsis. Am J Respir J Pediatr. 1994; 1224(1): 105-11; 42. Vertkin AL, Prokhorovich EA, Namazova LS, et al. Optimization of the empirical treatment of community-acquired pneumonia in patients with elderly. Russian Medical Journal 2002; 10(16): 708-812; 43. Mehr S, Doyle LW. Cytokines as markers of bacterial sepsis in newborn in-fants: a review. Pediatr Infect Dis J 2007; 19(9): 879-887; 44. Menender R, Martinez R, Reyes S Biomarkers improve mortality pre-diction diagnostic scales in community-acquired pneumonia. Thorax. 2009; 64 (7): 587-591; 45. Velkov VV. Presepsin - new highly effective biomarker of sepsis. Clinical and laboratory consilium 2012; 2(42): 56-62; 46. Popov DA, Plyushch MG, Yarustovskiy MB, et al. Monitoring the level of SCD14-ST (presepsin) in perioperative period of cardiac surgery patients. Anesthesiology and Reanimatology 2013; 3: 30-35; 47. Shozushima Т, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011; 17(6): 764-769; 48. Endo S, Suzuki Y, Takahashi G, Shozushima T, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. 2012; 18(6): 891-7; 49. State Standard. The standard of care for patients with pneumonia caused by Streptococcus Pneumoniae, pneumonia caused by Hemophilus influenzae (Pfeiffer-stick Afanasyev) bacterial pneumonia not elsewhere classified; pneumonia caused by other infectious agents, unclassified pneumonia; pneumonia without specifying pathogen; lung abscess with pneumonia (with specialized assistance). Moscow, 2007; 50. Azhgikhin IS. Prostaglandins - a new class of biologically active substances. In: Prostaglandins. Moscow: Medicine, 1978; p. 245-260; 51. Denisenko РР, Ter-Karapetyan VA. The role of unsaturated fatty acids in inflammation. In: Proceedings of Congress USA 1995; p. 59; 52. Denisenko РР, Isaeva SR, Denisenko NP, et al. Therapeutic and prophylactic use of essential unsaturated fatty acids (review). Clinical Pharmacology and Therapeutics 1997; 9: 47-52; 53. Burbello AT Omega-3 polyunsaturated fatty acids. In: Pharmacology: clinical application. St. Petersburg, 2005; p. 304; 54. Komarov Fl, Serebryanskaya MV. Clinical and immunological aspects of the different variants of the peptic ulcer. Therapeutic Archive 1990; 2(62): 38-43; 55. Burbello AT, Shabrov AV, Serebryakova VI, et al. Immunocorrecting effects of antioxidants and polyunsaturated fatty acids in certain diseases of the internal organs. International Journal Immunorehabilitation 2000; 2(2): 46; 56. Azhgikhin IS, Ter-Karapetyan VA, Gandel VG, et al. Docosahexaenoic and eicosapentaenoic acid: new pharmaceutical and medical aspects. Farmatsiya 1987; 36(2):80-89; 57. Burbello AT, Frelikh МР, Shabrov AV, et al. Polyunsaturated fatty acids as a means of prevention of acute asthma. Vestnik of the St. Petersburg State Medical Academy named after I.I. Mechnikov 2000; 1: 43-46; 58. Burbello AT, Frelikh МР, Serebryakova VI, etal. Changing the state of the antioxidant status of the immune system and some patients influenced omega-3 polyunsaturated fatty acids and antioxidants. In: Proceedings of the VII Russian National Congress «Chelovek i lekarstvo». Moscow, 2000; p. 393-394; 59. Hurst S, Zainal Z, Caterson В, et al. Dietary fatty acids and arthritis. Prostaglandins Leucot Essent Fatty Acids 2010; 82(4-6): 315-8; 60. Gaykovaya LB, Kukharchik GA, Bogdanova VG, et al. Laboratory markers in the evaluation of anti-inflammatory effects of omega-3 polyunsaturated fatty acids. Cytokines and Inflammation 2011; 1.

2014_01-01_173-178.pdf263.36 KB

No votes yet